Should we apply sorafenib in hepatocellular carcinoma patients with microvascular invasion after curative hepatectomy?

OBJECTIVE: Microvascular invasion (MVI) has been proved to be an independent risk factor for the recurrence of HCC. If promptly treated, the recurrence rate can be reduced and the total survival time can be prolonged. The aim of this study is to analyze the effect of sorafenib on the clinical outcom...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Yun, Zhang, Zeyu, Zhou, Yufan, Yang, Jiajin, Hu, Kuan, Wang, Zhiming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2019
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6334782/
https://www.ncbi.nlm.nih.gov/pubmed/30666133
http://dx.doi.org/10.2147/OTT.S187357

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6334782/
https://www.ncbi.nlm.nih.gov/pubmed/30666133
http://dx.doi.org/10.2147/OTT.S187357

Ejemplares similares